definiens: ): ( i ) all [COMPANY] Compounds ( as defined in the Research Collaboration Agreement ), as set forth onSchedule 3.1(a)(i ) attached hereto wherein all chemical structures are identified by corresponding compoundreference numbers as listed within the electronic database named ‘ JAK3 Searchable # 2108 ’ that was shared betweenthe parties ( the ), including all inventions relating thereto;(ii ) all Patent Rights owned by the Company that cover or would be infringed by the Manufacture, use, Development or Commercialization of the Acquired Compounds, the Acquired Compound Derivatives or theAcquired Compound Products, as set forth on Schedule 3.1(a)(ii ) attached hereto ( the ) and all patent prosecution documents and files relating thereto;(iii ) all written protocols relating to the synthesis and/or screening of any of the Acquired Compounds orotherwise utilized in connection with the synthesis and/or screening of compounds to identify JAK-3 KinaseInhibitors under the Research Collaboration, as set forth on Schedule 3.1(a)(iii ) attached hereto;(iv ) all data, databases, results, research and development plans, experiments, laboratory notebooks, materials, software, methods and assays, screening protocols and other Know - How or information relating primarily toactivities conducted by, or on behalf of, the Company and/or its Affiliates under the Research Collaboration, as setforth on Schedule 3.1(a)(iv ) attached hereto ; and(v ) all physical quantities of the Acquired Compounds in the possession of the Company or its Affiliates or anyThird Party on behalf of the Company and/or its Affiliates, as set forth on Schedule 3.1(a)(v ) attached hereto